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Abstract
National estimates of antiretroviral therapy (ART) adherence and adherence support services 
utilization are needed to inform efforts to improve the health of HIV-infected persons in the 
United States. In a nationally representative sample of HIV-infected adults receiving medical care, 
86% self-reported taking all ART doses in the past 72 hours. Overall, 20% reported using 
adherence support services and 2% reported an unmet need for services. If all nonadherent persons 
not receiving adherence support and all persons with a self-perceived unmet need for adherence 
support accessed services, resources to support ~42,673 additional persons would be needed. 
Factors associated with lower adherence included younger age, female gender, depression, 
stimulant use, binge alcohol use, greater than once-daily dosing, longer time since HIV diagnosis, 
and patient beliefs. Predictors of adherence are multifactorial so multiple targeted strategies to 
improve adherence are warranted. Providing adherence support services to all those in need may 
require additional resources.
Maximizing the percentage of HIV-infected persons achieving each step of the HIV care 
continuum is essential for reducing morbidity and mortality and minimizing the likelihood 
of onward HIV transmission (Cohen et al., 2011; Hall et al., 2013). In the United States, the 
largest drop-offs in the HIV care continuum are retention (55% of those diagnosed are not 
retained in care) and viral suppression (22% of those prescribed antiretroviral therapy [ART] 
do not achieve viral suppression; Hall et al., 2013). As was noted by Gardner and colleagues 
(Gardner, McLees, Steiner, Del Rio, & Burman, 2011), adherence is a key reason for this 
suboptimal level of suppression. While ART adherence is extremely well studied, there are 
no nationally representative US estimates of adherence among HIV-infected adults in care 
since 1998 (Kumar & Encinosa, 2010) and, to our knowledge, no estimates of the size of the 
HIV-infected population that needs adherence support services. Estimating the size of the 
population in need of adherence support and the factors associated with nonadherence can 
inform resource planning and targeted adherence interventions to improve population-level 
health outcomes among HIV-infected persons.
Moreover, recent changes in ART prescription practices and drug development require a 
renewed focus on the challenges of adherence. The latest clinical guidelines for HIV care 
recommend offering ART to all patients regardless of CD4+ T-lymphocyte cell (CD4) count 
Address correspondence to Linda Beer, PhD, Clinical Outcomes Team, Behavioral & Clinical Surveillance Branch, Division of HIV/
AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, MS-E46, Atlanta, GA 30329. LBeer@cdc.gov. 
HHS Public Access
Author manuscript
AIDS Educ Prev. Author manuscript; available in PMC 2015 September 23.
Published in final edited form as:













(Panel on Antiretroviral Guidelines for Adults and Adolescents, 2013), which may have 
important implications for efforts to improve adherence. As more patients are prescribed 
ART, there may be a corresponding increase in the number of persons in need of adherence 
support. In addition, adherence may be more challenging for persons with less advanced 
disease if feeling healthy affects their beliefs about the necessity of adherence (Gonzalez et 
al., 2007). Even without changes in ART prescription guidelines, decreases in mortality and 
a relatively stable annual number of new infections has resulted in more persons being 
prescribed ART for a longer duration than was seen previously. On the other hand, better-
tolerated regimens with less frequent dosing are now available, which may improve 
adherence among HIV-infected persons. Finally, because the success of “treatment as 
prevention” requires adherence to ART (Celum, Hallett, & Baeten, 2013), understanding the 
factors associated with adherence among HIV-infected persons may have important public 
health benefits.
This analysis addresses the following questions: What percentage of HIV-infected adults in 
care in the United States self-reported adherence to all ART doses during the past 3 days? Is 
self-reported adherence associated with viral suppression? What factors are independently 
associated with adherence in this population? Finally, what percentage of people use or have 
an unmet need for adherence support services?
METHODS
MEDICAL MONITORING PROJECT (MMP) DESIGN AND DATA COLLECTION
The Medical Monitoring Project (MMP) is a national HIV surveillance system designed to 
produce representative estimates of behavioral and clinical characteristics of HIV-infected 
adults receiving medical care in the United States (Blair et al., 2014; Frankel et al., 2012; 
McNaghten et al., 2007). MMP is a complex-sample, cross-sectional survey. For the 2009 
data collection cycle, US states and territories were sampled first, followed by facilities 
providing HIV care, and then by HIV-infected adults (persons aged 18 years and older) who 
had at least one medical care visit during January–April 2009 at participating facilities. Data 
were collected through face-to-face interviews and medical record abstractions from June 
2009 through May 2010. All sampled states and territories participated in MMP: California 
(including the separately funded jurisdictions of Los Angeles County and San Francisco), 
Delaware, Florida, Georgia, Illinois (including Chicago), Indiana, Michigan, Mississippi, 
New Jersey, New York (including New York City), North Carolina, Oregon, Pennsylvania 
(including Philadelphia), Puerto Rico, Texas (including Houston), Virginia, and 
Washington. Of 603 facilities sampled in participating states, 461 participated in MMP 
(facility response rate, 76%). Most of the HIV care facilities sampled were private practices, 
(60%, 95% confidence interval [CI] [51, 69]), followed by hospital-based facilities (30%, CI 
[26, 34]) and community health centers (19%, CI [13, 25]). The remainder were clinical 
research facilities (10%, CI [8, 13]), state or local health department clinics (5%, CI [3, 7]), 
community-based service organizations (4%, CI [2, 6]), and Veterans Administration 
facilities (4%, CI [2, 5]). A facility could belong to multiple categories. Of the 9,338 persons 
sampled from participating facilities, 4,217 completed the interview and had their medical 
records abstracted (patient-level response rate, 51%). Patients were recruited to participate in 
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MMP through one of two strategies: enrollment by MMP staff or enrollment by facility 
staff. The strategy depended on clinic needs, project area needs, local requirements, and the 
number of patients selected from a given facility.
Data were weighted on the basis of known probabilities of selection at state or territory, 
facility, and patient levels (Harding, Iachan, Johnson, Kyle, & Skarbinski, 2013). In 
addition, to adjust for potential nonresponse bias, predictors of nonresponse were 
determined from analysis of data from all sampled facilities and 88% of sampled patients. 
Data were then weighted by using predictors of patient-level response, including facility 
size, race/ethnicity, time since HIV diagnosis, and age group (Heeringa, West, & Berglund, 
2010; Särndal & Lundström, 2005). After weighting for probability of selection and 
nonresponse, the 4,217 participants in the 2009 MMP data collection cycle were estimated 
to represent a population of 421,186 (CI [378,187, 464,186) HIV-infected adults receiving 
medical care in the United States during January–April 2009.
ETHICS STATEMENT
In accordance with the federal human subjects protection regulations at 45 Code of Federal 
Regulations 46.101c and 46.102d (Protection of Human Subjects, 2009) and with the 
Guidelines for Defining Public Health Research and Public Health Non-Research (Centers 
for Disease Control and Prevention, 2010), MMP was determined by the National Center for 
HIV, Viral Hepatitis, STD and TB Prevention's Office of the Associate Director for Science 
at the Centers for Disease Control and Prevention (CDC) to be a nonresearch, public health 
surveillance activity used for disease control program or policy purposes. As such, MMP is 
not subject to human subjects regulations, including federal institutional review board (IRB) 
review. Participating states or territories and facilities obtained local institutional review 
board approval to conduct MMP if required locally. Informed consent was obtained from all 
interviewed participants.
ANALYTIC METHODS
In this analysis we included MMP participants who reported current ART use and provided 
complete information about adherence to ART dosing. This analytic sample consisted of 
3,606 persons representing 362,049 HIV-infected adults receiving medical care (CI 
[324,252, 399,846]). We estimated the prevalence of self-reported 100% adherence to ART 
doses (dose adherence) in the past 3 days using AIDS Clinical Trials Group measures 
(Chesney et al., 2000). These questions asked about each medication the patient was 
prescribed at the time of interview and how often the participant missed a dose over a 
specified time frame. If the participant only took part of a dose, they were instructed to 
report this as missing the dose. A card with pictures of antiretroviral medications was used 
to aid recall. Additionally, participants were asked about adherence to medication schedule 
(schedule adherence) and, among those with special instructions for taking their medications 
(i.e., with food), about adherence to those instructions (instruction adherence) in the past 3 
days.
We used modified Rao-Scott chi-square tests to assess the relationship between adherence 
and two measures of viral suppression from the medical record, (1) most recent viral load 
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undetectable or <= 200 copies/ml (recent viral suppression) and (2) all viral loads in past 12 
months undetectable or <= 200 copies/ml (durable viral suppression). We also examined the 
relationship between adherence and self-reported use of, and unmet need for, adherence 
support services, defined for the participant as “Professional help remembering to take your 
HIV medicines on time or correctly.” We then used multivariable logistic regression to 
identify factors independently associated with adherence, using a backward elimination 
modeling strategy with p < 0.10 inclusion and p < 0.05 retention criteria. Candidate 
variables for inclusion in the models are listed in Table 1, with the exception of the sexual 
behavior and orientation variable, which was excluded due to collinearity with gender. 
Stimulant use was defined as injection or noninjection use of methamphetamines, other 
amphetamines, cocaine, or crack. Binge drinking was defined as five or more drinks in one 
sitting for men and four or more drinks in one sitting for women. A dose of ART was 
defined as either a single tablet or multiple tablets taken concurrently. All measures were 
based on in person interviews, with the exception of the HIV disease stage and viral 
suppression variables, which were based on medical record abstraction. All analyses 
accounted for clustering, unequal selection probabilities, and patient and facility 
nonresponse. Data were weighted for nonresponse (Heeringa et al., 2010; Särndal & 
Lundström, 2005) and all analyses accounted for the complex sample design and unequal 
selection probabilities by using the survey procedures in SAS 9.3 (SAS Institute Inc., Cary, 
NC, USA) and SUDAAN 10.0.1 (RTI International, Research Triangle Park, NC, USA). All 
percentages reported are weighted to account for the complex sample design.
RESULTS
Most HIV-infected persons receiving care were 40 or older, male, had clinical or 
immunologic AIDS, had been HIV-diagnosed for 10 or more years, and were prescribed one 
daily ART dose (Table 1). Reported dose adherence was 86%, schedule adherence was 72%, 
and instruction adherence was 69% (Table 2). Overall, 60% reported being adherent to all 
three measures over the past 3 days.
Among persons with dose adherence information, all forms of self-reported adherence were 
associated with having a suppressed viral load at one's most recent test and with durable 
viral suppression over the past 12 months (Table 2). Examination of prevalence ratios 
indicated that dose adherence was the best predictor of recent and durable viral suppression. 
Persons reporting dose adherence were 25% and 33% more likely to have recent and durable 
viral suppression, respectively. The estimated number of dose nonadherent persons in the 
United States was 52,024 (CI [44,886–59,162).
In multivariable analysis, persons age 18–29 and 30–39 compared to those age 50 and older 
(adjusted prevalence ratio [aPR] 0.86, CI [0.79, 0.94] and aPR 0.94, CI [0.90, 0.99], 
respectively), women compared to men (aPR 0.96, CI [0.93, 0.99]), those who were 
depressed (aPR 0.96, CI [0.93, 1.00]), used stimulant drugs (aPR 0.87, CI [0.81, 0.92]), 
binge drank (aPR 0.90, CI [0.86, 0.94]), had more than one daily ART dose (aPR 0.95, CI 
[0.92, 0.98]), were bothered by side effects (aPR 0.95, CI [0.90, 0.99]), were unsure if they 
could take medications as directed (aPR 0.69, CI [0.61, 0.78]), were unsure if their body will 
become resistant to HIV medications if they do not take medications exactly as instructed 
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(aPR 0.94, CI [0.90, 0.99]), and were HIV-infected for more than 10 years compared to less 
than 5 years (aPR 0.95, CI [0.91, 0.98]) were independently less likely to report adherence 
to ART doses (Table 3). Dose adherence did not vary by HIV disease stage, with 85% of 
persons with AIDS reporting dose adherence compared to 87% of persons without AIDS 
and with nadir CD4 counts 200–499 cells/μL, and 83% of persons without AIDS and nadir 
CD4 counts ≥ 500 cells/μL (p = 0.3433) (Table 1).
Overall, 20% (CI [17, 23]) reported using adherence support services, 2% (CI [1, 2]) 
reported an unmet need for adherence support services, and 78% (CI [75, 81]) reported not 
using or needing adherence support services (Table 4). Use of these services was 
significantly associated with dose adherence (P < 0.0001), with 83% (CI [80, 86]) of those 
reporting use of adherence support also reporting 100% dose adherence. In contrast, among 
the group with an unmet need for adherence support, only 46% (CI [34, 59]) were dose 
adherent. Approximately 13% (CI [11, 15]) of those not perceiving themselves in need of 
adherence support services were dose nonadherent, and we estimate the number of persons 
in this group in the United States to be 36,167 (CI [29,956, 42,379]), or 10% (CI [9, 11]) of 
all HIV-infected persons taking ART. The estimated number of persons reporting an unmet 
need for adherence support in the United States (regardless of their reported adherence) was 
6,505 (CI [4,736, 8,275]), or 2% (CI [1, 3]) of all HIV-infected persons on ART.
In all, we estimate that if all nonadherent persons not receiving adherence support and all 
those with a self-perceived unmet need for adherence support were referred to services, this 
would require resources to support approximately 42,673 (CI [36,249, 49,097]) additional 
persons nationally or 12% (CI [10, 13]) of all HIV-infected person in medical care on ART. 
Compared to those not needing additional adherence support services, the demographics of 
this group are similar in terms of race and sexual orientation (data not shown). However, 
persons in need of adherence support were more likely than those with no need for 
additional adherence support to be over 50, female, and diagnosed for more than 5 years (all 
p < 0.05).
DISCUSSION
Similar to other recent studies using self-reported measures (O'Connor et al., 2013; Tedaldi 
et al., 2012), we found that 86% of HIV-infected persons reported 100% dose adherence. 
However, 40% were nonadherent to at least one aspect of their regimen. All measures of 
self-reported adherence correlated highly with recent and durable viral suppression, but self-
report of dose adherence was the most highly predictive of both recent and durable viral 
suppression. Recent guidelines for improving adherence recommend routine collection of 
self-reported adherence (Thompson et al., 2012) and tools have been developed to assist 
providers with implementation (Amico, Zuniga, Wilson, Gross, & Young, 2013). Regularly 
asking questions about missed ART doses is a simple intervention that remains a standard of 
care for HIV-infected persons.
Consistent with the body of literature on ART adherence (Chesney, 2003), factors found to 
be associated with poorer adherence fell into four broad areas: demographics (younger age, 
female gender), psychosocial comorbidities (depression, stimulant use, binge drinking), 
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regimen characteristics (dosing frequency, side effects), and patient beliefs (self-efficacy, 
beliefs about the need for adherence to prevent resistance). We also found poorer adherence 
among those who had been diagnosed with HIV for 10 or more years. Although in bivariate 
analysis, we found lower adherence among nonwhite persons and those with lower 
socioeconomic status, these associations were no longer significant in multivariate logistic 
regression models.
These findings suggest several areas for intervention that could improve adherence at the 
population level. First, with regard to demographic subpopulations more likely to be 
nonadherent independent of other factors associated with nonadherence, interventions that 
specifically address the needs of youth and women are warranted. Younger persons may 
have different health-related concerns and motivations than older persons (Barclay et al., 
2007), which could be incorporated into adherence messages. Similarly, the issues faced by 
women living with HIV are different from those of men (Interagency Federal Working 
Group, 2013), so tailored programs for women that address these barriers may be helpful.
Addressing psychosocial comorbidities such as depression and substance use problems 
among patients may improve their adherence, as well as their general health and well-being. 
A recent meta-analysis found that treating depression enhances adherence (Sin & Dimatteo, 
2014), although effective adherence interventions for HIV-infected drug users may be more 
challenging (Binford, Kahana, & Altice, 2012). Ensuring providers have access to case 
managers and appropriate referrals to mental health and substance abuse treatment may help.
Minimizing side-effects and dosing are ways providers may modify treatment regimens to 
support optimal adherence among their patients. Single tablet regimens have been found to 
be effective in improving adherence and enhancing patient quality of life (Aldir, Horta, & 
Serrado, 2013), and our results show that patients with once-daily dosing were more likely 
to be adherent.
Addressing patient beliefs about adherence and ART are also important for sustained 
behavior change. Regularly assessing a patient's self-efficacy about taking medications and 
beliefs about the consequences of nonadherence may also provide information that allows 
for appropriate intervention to improve adherence. The Information-Motivation-Behavioral 
Skills (IMB) model points to the importance of these factors for adherence and has served as 
the basis for several effective adherence interventions (Fisher, Amico, Fisher, & Harman, 
2008; Horvath, Smolenski, & Amico, 2014). Peer-based adherence support models have also 
shown promise in improving adherence (Kenya, Chida, Symes, & Shor-Posner, 2011).
Finally, our finding that persons diagnosed for 10 or more years were less adherent has 
important implications. Given that an estimated 54% of HIV-infected persons receiving 
medical care have been diagnosed 10 or more years (Blair et al., 2014) and advances in 
treatment mean that life expectancy for HIV-infected persons can approach that of the 
general population, more efforts to promote adherence in persons with long-standing HIV 
infection may be warranted. Our results support the importance of ongoing adherence 
monitoring and support, even among persons with good adherence, as adherence is a 
dynamic behavior that may be hard for some to sustain over long periods of time.
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We estimate that one in ten HIV-infected persons on ART is nonadherent and does not 
perceive him or herself to need professional assistance with adherence support. Providers 
can address this incongruity and increase knowledge about the negative effects of 
nonadherence by regularly integrating adherence education and support into all clinical 
encounters (CDC, n.d.; Thompson et al., 2012). We found that patients using professional 
adherence support reported high levels of dose adherence. We estimate that if all 
nonadherent HIV-infected persons who were not already using adherence support and those 
with a self-perceived unmet need for adherence support were referred to adherence support 
services, this would require resources to support approximately 42,673 additional persons or 
12% of all HIV-infected persons on ART. Weiser and colleagues found that, while 83% of 
Ryan White HIV/ AIDS Program funded HIV care facilities provided onsite adherence 
support counseling, these services were only available at 35% of nonfunded facilities 
(Weiser, Beer, Do, Shah, & Skarbinski, 2012).
This analysis is subject to several limitations. Our adherence measures are self-reported, a 
method found to overestimate adherence; however, in this and other studies self-reported 
measures were associated with clinical markers such as viral load and other more objective 
means of assessing adherence (Chesney, 2006; Simoni et al., 2006). While we find a strong 
association between our measure of dose adherence in the past 3 days and the patient's most 
recent viral load, the measures were not necessarily contemporaneous; however, the viral 
load test always preceded the self-report of adherence. It is possible that if adherence and 
viral load were measured simultaneously the associations would be stronger than those we 
present. In addition, the data were collected during 2009–2010, and since then treatment 
guidelines have moved towards recommending ART prescription at higher CD4+ T-
lymphocyte cell counts and more tolerable single tablet regimens have been developed. To 
the extent that this has changed the population taking ART, levels of adherence and factors 
associated with adherence among the current HIV patient population may be different than 
those identified here. However, given that an estimated 88% of HIV-infected persons 
receiving care were already taking ART in 2009–2010 (Blair et al., 2014) and that adherence 
behaviors and many of the social and psychological forces that shape them are unlikely to 
vary widely from year to year, we have confidence in the relevance of our findings for the 
present time period. Another potential limitation is that, while the data were adjusted to 
minimize nonresponse bias based on known characteristics of nonresponders, the possibility 
of residual nonresponse bias exists. Although the characteristics of our sample in terms of 
age, HIV disease stage, and length of time since HIV diagnosis are similar to those of all 
HIV diagnosed persons (CDC, 2013), it is possible that persons who did not participate in 
MMP may be less adherent compared to those who did participate, and the factors 
associated with their adherence may be different than those presented here. In addition, the 
precision of adherence estimates among some subpopulations, such as transgender persons, 
may have been limited by small sample sizes. Further, because MMP has a cross-sectional, 
observational design, causality cannot be determined. Finally, because the sample design 
does not allow for assessment of regional differences and the focus of this analysis is 
adherence in the United States, geographic variation in adherence and its correlates was not 
assessed.
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These are the first national estimates of ART adherence in the post-HAART era, and were 
collected from a diverse, population-based sample of HIV-infected patients receiving care in 
a wide range of facilities with varying characteristics (e.g., small and large, urban and rural). 
In addition, we were able to comprehensively assess a wide range of sociodemographic, 
regimen, and health belief factors within this population. As such, our estimates help inform 
how we are doing as a nation with regard to adherence—one of the primary determinants of 
treatment success for HIV-infected persons and the key to maximizing the final step in the 
HIV care continuum—and highlight key barriers to improvements in adherence. Although 
CDC has identified several effective behavioral interventions that improve adherence 
(Charania et al., 2014), information about which interventions are most effective for which 
populations in specific settings is still needed (Amico & Orrell, 2013; Herbst et al., 2012). 
Our findings support the importance of multiple targeted strategies to improve adherence: 
youth- and woman-centered care; treatment of psychosocial comorbidities; promotion of 
less complex and more tolerable regimens; improving patients’ information, motivation, and 
skills regarding adherence; and continued monitoring to promote consistent adherence over 
time.
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